Divi's Laboratories shares gain 6% after JPMorgan upgrade; Goldman raises earnings estimates after strong Q2
Motilal said the company is well-positioned to secure business in the custom synthesis segment, given its scientific capabilities across peptides, contrast media and generics, large-scale commercial manufacturing…
Divi's Laboratories+3.24%
